Sign In
Buy LFVN
Lifevantage Earnings Calls
| Release date | May 06, 2026 |
| EPS estimate | $0.160 |
| EPS actual | $0.120 |
| EPS Surprise | -25.00% |
| Revenue estimate | 47.774M |
| Revenue actual | 43.716M |
| Revenue Surprise | -8.49% |
| Release date | Feb 04, 2026 |
| EPS estimate | $0.190 |
| EPS actual | $0.150 |
| EPS Surprise | -21.05% |
| Revenue estimate | 54.402M |
| Revenue actual | 48.931M |
| Revenue Surprise | -10.06% |
| Release date | Nov 04, 2025 |
| EPS estimate | $0.170 |
| EPS actual | $0.180 |
| EPS Surprise | 5.88% |
| Revenue estimate | 54.402M |
| Revenue actual | 58.44M |
| Revenue Surprise | 7.42% |
| Release date | Sep 04, 2025 |
| EPS estimate | $0.170 |
| EPS actual | $0.170 |
| Revenue estimate | 57.931M |
| Revenue actual | 55.114M |
| Revenue Surprise | -4.86% |
Last 4 Quarters for Lifevantage
Below you can see how LFVN performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Sep 04, 2025 |
| Price on release | $13.46 |
| EPS estimate | $0.170 |
| EPS actual | $0.170 |
| Date | Price |
|---|---|
| Aug 28, 2025 | $13.10 |
| Aug 29, 2025 | $13.10 |
| Sep 02, 2025 | $13.55 |
| Sep 03, 2025 | $13.57 |
| Sep 04, 2025 | $13.46 |
| Sep 05, 2025 | $12.11 |
| Sep 08, 2025 | $11.44 |
| Sep 09, 2025 | $11.84 |
| Sep 10, 2025 | $11.23 |
| 4 days before | 2.75% |
| 4 days after | -16.57% |
| On release day | -10.03% |
| Change in period | -14.27% |
| Release date | Nov 04, 2025 |
| Price on release | $7.00 |
| EPS estimate | $0.170 |
| EPS actual | $0.180 |
| EPS surprise | 5.88% |
| Date | Price |
|---|---|
| Oct 29, 2025 | $8.15 |
| Oct 30, 2025 | $8.07 |
| Oct 31, 2025 | $8.19 |
| Nov 03, 2025 | $7.34 |
| Nov 04, 2025 | $7.00 |
| Nov 05, 2025 | $7.31 |
| Nov 06, 2025 | $6.75 |
| Nov 07, 2025 | $7.40 |
| Nov 10, 2025 | $7.26 |
| 4 days before | -14.11% |
| 4 days after | 3.71% |
| On release day | 4.43% |
| Change in period | -10.92% |
| Release date | Feb 04, 2026 |
| Price on release | $5.55 |
| EPS estimate | $0.190 |
| EPS actual | $0.150 |
| EPS surprise | -21.05% |
| Date | Price |
|---|---|
| Jan 29, 2026 | $5.46 |
| Jan 30, 2026 | $5.30 |
| Feb 02, 2026 | $5.51 |
| Feb 03, 2026 | $5.36 |
| Feb 04, 2026 | $5.55 |
| Feb 05, 2026 | $4.62 |
| Feb 06, 2026 | $5.03 |
| Feb 09, 2026 | $5.07 |
| Feb 10, 2026 | $4.93 |
| 4 days before | 1.65% |
| 4 days after | -11.17% |
| On release day | -16.76% |
| Change in period | -9.71% |
| Release date | May 06, 2026 |
| Price on release | $6.00 |
| EPS estimate | $0.160 |
| EPS actual | $0.120 |
| EPS surprise | -25.00% |
| Date | Price |
|---|---|
| Apr 30, 2026 | $5.05 |
| May 01, 2026 | $5.43 |
| May 04, 2026 | $5.13 |
| May 05, 2026 | $5.49 |
| May 06, 2026 | $6.00 |
| May 07, 2026 | $5.02 |
| May 08, 2026 | $5.34 |
| May 11, 2026 | $5.14 |
| May 12, 2026 | $5.15 |
| 4 days before | 18.81% |
| 4 days after | -14.17% |
| On release day | -16.33% |
| Change in period | 1.98% |
Lifevantage Earnings Call Transcript Summary of Q1 2026
LifeVantage reported Q1 FY2026 net revenue of $47.6M, up 0.7% year-over-year, with adjusted EBITDA of $3.9M (down $0.5M vs. prior year) driven by lower contribution margin and higher commission/incentive mix partly offset by lower SG&A. The company closed the strategic LoveBiome acquisition on October 1, positioning LifeVantage in the fast-growing gut microbiome market (P84 product) and completed rapid systems integration (cutover completed Oct/Nov), with early positive consultant engagement and cross-selling training underway. Progress was made on a Shopify e-commerce partnership (pilot planned this fiscal year). Q1 gross margin was 79.5%; cash was $13.1M with no debt and a $5M revolver. Capital allocation included $0.6M of share repurchases and a quarterly cash dividend of $0.045/share; $16.7M remains on the repurchase authorization. Management reiterated FY26 guidance: revenue $225M–$240M (including LoveBiome), adjusted EBITDA $23M–$26M, and adjusted EPS $1.00–$1.15. Company expects H2 weighting due to seasonality of MindBody and LoveBiome ramp; full-year effective tax rate expected around 25%.
